Partnership Track Record Ongoing biopharma partnerships and a notable engagement with Bristol-Myers Squibb demonstrate credible demand from large pharma and provide reference opportunities to other top tier companies.

Digital Twins Value The platform’s digital metabolic twins enable better patient selection and trial simulations, potentially increasing success rates and reducing trial sizes—an attractive ROI story for R&D teams.

Indication Focus Pipeline covers oncology and cardio-metabolic diseases such as renal cell carcinoma, MASH and obesity, offering sales angles to asset teams in these areas and room to expand into additional indications.

Unique Tech Edge AI driven metabolomics with patented methods and enhanced metabolite detection positions ReviveMed as a differentiated supplier of mechanistic insights and biomarker discovery to pharma pipelines.

Go To Market With a lean team and strong Cambridge MA ecosystem, ReviveMed can scale through licensing, joint development, or services arrangements with pharma and CRO partners, leveraging existing relationships to accelerate deals.